Skip to content
Biogen Inc (NASDAQ: BIIB) is caught in more than one legal wrangle with generic companies over patents related to its key multiple sclerosis drug Tecfidera, which was approved by the FDA in March 2013.The Biogen Analyst: Morgan Stanley analyst Matthew Harrison has an Underweight rating on Biogen with a $263 price target. The Biogen Thesis: Two legal catalysts in the coming weeks will help determine when a generic version of Tecfidera may be launched and by which companies, Harrison said in a Wednesday note. (See his track record here.)These catalysts are significant for Biogen, as Tecfidera is estimated to rake in about 30% of the company's total sales in 2020, the analyst said. If a generic is launched, Biogen stands to lose significant Tecfidera market share, and the price of the drug is likely to erode steeply within the first year of generic market entry, he said.Vumerity, Biogen's prodrug version of...
Twitter’s thin veil of security went into full meltdown at 19:00 UTC on Wednesday. Within hours, even Barack Obama’s account was compromised....
Yahoo Finance’s Rick Newman joins The Final Round to break down a recent poll taken by Quinnipiac University saying that Biden’s lead widen over Trump by 15 points, holding 52% over Trump’s 32% from the poll's data. ...
